Caroline Junqueira1,2,3, Camila R R Barbosa4, Pedro A C Costa4, Andréa Teixeira-Carvalho4, Guilherme Castro4, Sumit Sen Santara5,6, Rafael P Barbosa5,6, Farokh Dotiwala5,6, Dhelio B Pereira7, Lis R Antonelli4, Judy Lieberman8,9, Ricardo T Gazzinelli10,11,12. 1. Instituto René Rachou, Fundação Oswaldo Cruz, Belo Horizonte, Brazil. carolinejunqueira@minas.fiocruz.br. 2. Program in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA, USA. carolinejunqueira@minas.fiocruz.br. 3. Department of Pediatrics, Harvard Medical School, Boston, MA, USA. carolinejunqueira@minas.fiocruz.br. 4. Instituto René Rachou, Fundação Oswaldo Cruz, Belo Horizonte, Brazil. 5. Program in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA, USA. 6. Department of Pediatrics, Harvard Medical School, Boston, MA, USA. 7. Centro de Pesquisas em Medicina Tropical, Porto Velho, Brazil. 8. Program in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA, USA. judy.lieberman@childrens.harvard.edu. 9. Department of Pediatrics, Harvard Medical School, Boston, MA, USA. judy.lieberman@childrens.harvard.edu. 10. Plataforma de Medicina Translacional, Fundação Oswaldo Cruz, Ribeirão Preto, Brazil. ricardo.gazzinelli@umassmed.edu. 11. Departamento de Bioquímica e Imunologia, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil. ricardo.gazzinelli@umassmed.edu. 12. Division of Infectious Disease and Immunology, University of Massachusetts Medical School, Worcester, MA, USA. ricardo.gazzinelli@umassmed.edu.
Abstract
Plasmodium vivax causes approximately 100 million clinical malaria cases yearly1,2. The basis of protective immunity is poorly understood and thought to be mediated by antibodies3,4. Cytotoxic CD8+ T cells protect against other intracellular parasites by detecting parasite peptides presented by human leukocyte antigen class I on host cells. Cytotoxic CD8+ T cells kill parasite-infected mammalian cells and intracellular parasites by releasing their cytotoxic granules5,6. Perforin delivers the antimicrobial peptide granulysin and death-inducing granzymes into the host cell, and granulysin then delivers granzymes into the parasite. Cytotoxic CD8+ T cells were thought to have no role against Plasmodium spp. blood stages because red blood cells generally do not express human leukocyte antigen class I7. However, P. vivax infects reticulocytes that retain the protein translation machinery. Here we show that P. vivax-infected reticulocytes express human leukocyte antigen class I. Infected patient circulating CD8+ T cells highly express cytotoxic proteins and recognize and form immunological synapses with P. vivax-infected reticulocytes in a human leukocyte antigen-dependent manner, releasing their cytotoxic granules to kill both host cell and intracellular parasite, preventing reinvasion. P. vivax-infected reticulocytes and parasite killing is perforin independent, but depends on granulysin, which generally efficiently forms pores only in microbial membranes8. We find that P. vivax depletes cholesterol from the P. vivax-infected reticulocyte cell membrane, rendering it granulysin-susceptible. This unexpected T cell defense might be mobilized to improve P. vivax vaccine efficacy.
Plasmodium vivax causes approximately 100 million clinical malaria cases yearly1,2. The basis of protective immunity is poorly understood and thought to be mediated by antibodies3,4. CytotoxicCD8+ T cells protect against other intracellular parasites by detecting parasite peptides presented by human leukocyte antigen class I on host cells. CytotoxicCD8+ T cells kill parasite-infected mammalian cells and intracellular parasites by releasing their cytotoxic granules5,6. Perforin delivers the antimicrobial peptide granulysin and death-inducing granzymes into the host cell, and granulysin then delivers granzymes into the parasite. CytotoxicCD8+ T cells were thought to have no role against Plasmodium spp. blood stages because red blood cells generally do not express human leukocyte antigen class I7. However, P. vivax infects reticulocytes that retain the protein translation machinery. Here we show that P. vivax-infected reticulocytes express human leukocyte antigen class I. Infected patient circulating CD8+ T cells highly express cytotoxic proteins and recognize and form immunological synapses with P. vivax-infected reticulocytes in a human leukocyte antigen-dependent manner, releasing their cytotoxic granules to kill both host cell and intracellular parasite, preventing reinvasion. P. vivax-infected reticulocytes and parasite killing is perforin independent, but depends on granulysin, which generally efficiently forms pores only in microbial membranes8. We find that P. vivax depletes cholesterol from the P. vivax-infected reticulocyte cell membrane, rendering it granulysin-susceptible. This unexpected T cell defense might be mobilized to improve P. vivax vaccine efficacy.
Although less virulent than P. falciparum, P.
vivax can cause life-threatening cerebral malaria, acute respiratory
distress syndrome, splenic rupture, hepatitis, severe anemia and thrombocytopenia, and
aggravate co-morbidities[9-11]. Both CD8+ T cell
IFNγ and cytotoxicity protect against the Plasmodium
circumsporozoite stages in hepatocytes[12-15], but CTLs
have no known role in fighting the blood stage, which is responsible for clinical
pathology. Because host cell invasion requires merozoite Duffy Binding Protein (DBP)
interaction with Retic Duffy Protein (DP)[16], inducing anti-DBP blocking antibodies is currently the main
strategy for an anti-P. vivaxmalaria vaccine[17]. However, anti-DBP vaccines have not been
successful in preclinical models and new vaccine approaches are badly needed[3,4].Although CD8+ T cells were not expected to recognize the blood
stage parasite, we analyzed activation markers on circulating
CD8+CD3+ T cells from uncomplicated P.
vivax malariapatients by flow cytometry (Fig. 1a,b,). These cells were primarily conventional TCRαβ
CD8+ T lymphocytes (Supplementary Fig. 1a,b). Although the
abundance of circulating CD8+ T cells and other lymphocytes (NK,
γδ T cells, NKT cells) that might contribute to malaria immune defense
did not differ in patients and healthy donors (HD) from the same endemic region of
Brazil (Supplementary Fig.
1c,d), CD8+ T cells from untreated patients had increased
expression of CD69 and HLA-DR activation markers and Ki67, a cell proliferation
indicator. These markers returned to levels similar to those in HDs 30–40 days
after treatment (AT) with chloroquine and primaquine and parasitological cure.
Circulating CD8+ T cell expression of cytotoxic granule GzmB, PFN and
GNLY was also significantly increased in malariapatients compared to HD from the
endemic area (Figs. 1c,d). These results confirm
studies suggesting that circulating CD8+ T cells are activated during
P. vivax, and to a lesser extent P. falciparum,
infection[18-22]. Acute patient plasma also contained ~6-fold
more GNLY than HD plasma by ELISA (Fig. 1e). To
identify the source of GNLY, we analyzed innate, innate-like and conventional
αβ T cells from HD and acute malariapatients for GNLY expression (Supplementary Fig. 1e). Most
GNLY+ circulating lymphocytes in patients were conventional
CD8+ T cells (69.7±1.2%). A higher proportion of
GNLY+ circulating lymphocytes were conventional
CD8+ T cells in patients than HD (p = 0.03). Fewer than
10% of the circulating GNLY+ cells were
CD4+ T cells, γδ T cells, NK or NKT cells in
either patients or HDs. Thus, conventional CD8+ T cells express most
of the GNLY in infected patients.
Figure 1
Increased frequency of activated CD8+ T cells in the
peripheral blood of P. vivax patients
Peripheral blood mononuclear cells (PBMCs) from healthy donors (HD) and
P. vivax malaria patients (Pv) were gated on
CD8+CD3+ T cells (gating strategy
described in Supplementary
Fig. 1) and analyzed for expression of activation markers and
cytotoxic granule proteins by flow cytometry. a,b, Shown are
representative flow plots (a) and the proportion of
CD8 T cells expressing CD69, HLA-DR and
Ki67 (b) malaria patients, before treatment (BT) and 30–40
days after treatment and parasitological cure (AT). n=8 biologically
independent samples/independent experiments. Statistical analysis was performed
by two-tailed parametric paired t-test at 95%
confidence interval (CI). c,d, Shown are representative flow plots
(c) and the proportion of peripheral blood
CD8+ T cells expressing GzmB, PFN, and GNLY
(d) HD and P. vivax (Pv) malaria patients BT.
n=5 biologically independent samples/independent experiments.
e, The levels of soluble GNLY in plasma of n=7 HD and
n=10 Pv patients BT were measured by ELISA as biologically independent
samples/independent experiments. (d,e) show mean ± SEM;
statistical analysis was performed by two-tailed non-parametric unpaired
t-test at 95% CI.
Based on these data, we hypothesized that CD8+ T cells in
P. vivaxmalariapatients might become activated by recognizing
iRetics, causing them to degranulate and release GNLY. Although P.
falciparum infects mature RBCs, asexual P. vivax
exclusively infects Retics, which retain the translation machinery, endoplasmic
reticulum (ER) and Golgi apparatus needed to produce cell surface proteins. An early
electron microscopy study suggested that human Retics weakly express HLA-I[7]. More recent transcriptome and proteome
analyses indicated that Retics express HLA and proteins involved in antigen
presentation[23,24], including the proteasome, TAP transporter and
cofactor TAPASIN, and the ER aminopeptidase ERAP1 (Table S1). We therefore used a pan-class I
antibody to compare HLA-I expression on the surface of uninfected and iRetics from
patients and HD. iRetics were identified by SYBR Green I staining[25], which stains parasite DNA but not Retic RNA
(Supplementary Fig. 2).
RBCs were gated based on size and granularity and CD235a (glycophorin A) staining (Fig. 2a), and Retics were identified as
CD235a+ and CD71+ (transferrin receptor). As
expected[24], acute malariapatient RBCs contained ~5-fold more Retics than HD (Fig.
2b). About half of patient Retics stained for HLA-I, compared to ~10%
in HD (p<0.0001) (Fig. 2c).
50.3 ± 7.0% of circulating Retics from patients were infected (Fig. 2d) and 57.1 ± 7.9% of iRetics
expressed HLA-I at levels comparable to that on B lymphocytes (Fig. 2e,f), but did not express HLA-DR (Fig. 2g). In contrast, <20% of uninfected SYBR
Green− Retics from patients expressed HLA-I
(p<0.0001). Imaging flow cytometry confirmed HLA-I expression
selectively on iRetics, compared to HD Retics (Fig.
2h).
Figure 2
Increased HLA-ABC in P. vivax infected reticulocytes
a, Gating strategy to evaluate P. vivax infection
and HLA-expression in reticulocytes. Top and bottom panels are representative
results from a healthy donor (HD) and P. vivax acute malaria
patient (Pv) before treatment (BT), respectively. Retics are
CD71+CD235a+ and SYBR Green detects
parasite DNA in iRetics. A pan-HLA class I antibody was used to analyze HLA
expression. This experiment was repeated four times with similar results.
b–d, Comparison of percent of retics in RBC gate (b),
percent of Retics that express HLA-I, (c) percent of SYBR
Green+ iRetics (d) in blood from HD (n=8) and Pv
BT patients (n=8). Shown are mean ± SEM; statistical analysis by
two-tailed non-parametric unpaired t-test at 95% CI.
e, Comparison of HLA-ABC expression in circulating uRetics and
iRetics in n=8 Pv BT samples, based on SYBR Green I and HLA staining of
CD235a+CD71+ Retics, representative
dot plot in (a). Shown are mean ± SEM; statistical analysis
used a two-tailed parametric paired t-test at 95% CI.
f,g, Comparison of HLA-ABC (f) and HLA-DR
(g) expression by HD uRetics and Pv iRetics and
CD19+ B cells. Light gray histograms are unstained and
darker gray histograms are stained cells. Shown are representative samples of 5
analyzed. h, Imaging flow cytometry of representative Pv uRetics
(top) and iRetics (bottom) stained for CD235a, SYBR Green, CD71, HLA-ABC and
HLA-DR. This experiment was repeated three times with similar results.
i, Immunoblot of cell lysates from 3 HD uRetics and 3 Pv
iRetics, loaded with 50 μg of protein per well and probed for the
antigen processing protein, TAP1 as well as β-actin and F-actin as
loading controls for HD uRetics and Pv BT iRetics, respectively. HD PBMCs were
used as a positive control (20 μg). This experiment was repeated three
times with similar results.
Cell surface HLA expression depends on antigenic peptide binding[26]. To confirm that iRetics have the
antigen processing machinery, we used density separation to isolate iRetics from 3
infected donors and uninfected Retics from 3 HD (Supplementary Fig. 3a,b) and analyzed their
expression of TAP1 by immunoblot. TAP1 was readily detected in iRetics, but not
uninfected Retics (Fig 2i). Thus, iRetics
selectively express HLA-I and TAP1, suggesting they might present malaria antigens to
CD8+ T cells.Long-term P. vivax culture has not been possible, limiting
studies of the immune response to blood stage infection. We developed a short-term
in vitro culture system[19,27,28] that enabled us to study the
CD8+ T cell response to iRetics. CD8+ T cells,
isolated by immunomagnetic selection from HD or patients, were cultured for 10 hr with
autologous, enriched uninfected Retics or iRetics, respectively (Supplementary Fig. 3c). iRetic incubation
activated infected donorCD8+ T cells to express CD69 and Ki67 and
produce IFNγ (Figs. 3a–c). In
contrast, HDCD8+ T cells did not respond to uninfected Retics. Both
patient and HDCD8+ T cells were activated by anti-CD3/anti-CD28.
Neither patient nor HDCD4+ T cells responded to iRetics (Fig. 3d). Importantly, HLA-I blocking, but not
control, antibody[29] prevented
iRetic-induced IFNγ production by CD8+ T cells, but did not
affect anti-CD3/anti-CD28 activation, which does not require HLA-I (Fig. 3e). Thus, circulating CD8+ T cells in
infected patients specifically recognize HLA-I-bound antigens on iRetics.
Figure 3
CD8+ T cells are activated by and lyse autologous
P. vivax-infected reticulocytes
a–d, Purified CD8+ or
CD4+ T lymphocytes from healthy donors (HD) or P.
vivax malaria patients (Pv) before treatment (BT) were cultured in
medium alone, with autologous uninfected Retics (uRetics), with purified
infected Retics (iRetics), or in the presence anti-CD3 and anti-CD28 and
analyzed by flow cytometry for the proportion of CD8+ T cells
staining for CD69 (a) and Ki67 (b) (n=5) or
intracellular IFNγ (c) (n=8); or
CD4+ T cells staining for intracellular IFNγ
(d) (n=6). e, IFNγ expression by
CD8+ T cells after stimulation with autologous uninfected
RBC (uRBC), purified iRetic or anti-CD3 and anti-CD28 in the presence of
anti-HLA-ABC or isotype control antibody (n=6). f,g,
Imaging flow cytometry analysis of immune synapse formation between
CD8+ T cells and autologous purified iRetics from Pv
patients or uRetics from HD (n=5). Shown are representative images of
immunological synapses between CD8+ T cells and purified
iRetics from a Pv sample (f) and mean ± SEM of the
proportion of CD8+ T cells forming synapses in 5 HD samples
with autologous uRetics and in 5 Pv patient BT samples with purified iRetics
(g). n=5 biologically independent samples/independent
experiments. Cells were stained for TCR and CD235a, CD3, HLA-ABC, and CD8 and
synapses were identified by the capping and co-localization of TCR, CD3, CD8 and
HLA-ABC where the T cell and RBC are juxtaposed. The enlarged overlay image on
the right corresponds to the bottom image. h,i, Survival of iRetics
after 12 hr incubation with medium or autologous CD8+ T cells
from Pv samples (n=5) (h) or of uRetics incubated with
medium or autologous HD CD8+ T cells (n=4)
(i), added at indicated E:T ratios, as assayed using
CFSE-labeled Retics. j, iRetic lysis after 12 hr incubation with
medium or autologous CD8+ T cells from Pv samples
(n=8), measured by LDH release. k, Frequency of
CD8+ T cells in the blood of 5 untreated Pv patients that
degranulate, assessed by CD107a staining, in response to indicated stimuli.
Shown are mean ± SEM; statistical analysis by non-parametric two-way
ANOVA (a–e), two-tailed non-parametric unpaired
t-test at 95% CI (g), and
non-parametric one-way ANOVA (h–k).
Imaging flow cytometry was next used to visualize the CD8+ T
cell-iRetic interaction, by staining co-cultures for HLA-I, CD235a, CD3, CD8 and TCR
(Fig. 3f,g). 10.9±2.2% of
circulating CD8+ T cells from 5 malaria donors formed immune synapses
in which TCR, CD3 and CD8 on the T cell capped and co-localized with HLA-I on autologous
iRetics. By contrast, <1% of HDCD8+ T cells formed
synapses with autologous Retics. To examine whether CD8+ T cells lyse
iRetics, CFSE-stained infected donor or HD Retics were co-cultured at different ratios
with autologous CD8+ T cells, and the persistence of CFSE-stained
cells was assessed by flow cytometry 12 hr later (Fig.
3h,i). Infected donorCD8+ T cells significantly reduced
the number of iRetics, but HDCD8+ T cells did not affect uninfected
Retics, indicating the specificity of iRetic lysis in infected patients. iRetic lysis by
autologous patientCD8+ T cells was confirmed by measuring LDH
release that increased with more CD8+ T cells (Fig. 3j). Activated CD8+ T cells kill
infected cells by cytotoxic granule exocytosis, which can be measured by externalization
of LAMP-1 (CD107a)[30]. After incubation
with autologous iRetics, but not uninfected RBCs, infected donorCD8+
T cells stained for surface CD107a, indicating that they degranulated (Fig. 3k). Moreover, the numbers of
CD107a+CD8+ T cells after iRetic co-culture
was not significantly different from the numbers that degranulated after
anti-CD3/anti-CD28 treatment, suggesting that most of the circulating activated
CD8+ CTLs in infected donors specifically recognize iRetics.CTLs kill other intracellular parasites in a PFN, GNLY and Gzm-dependent
manner[5]. To determine how
iRetics are lysed and whether P. vivax are killed in the process, we
first used imaging flow cytometry to determine whether AlexaFlour-488 (AF488)-labeled
GNLY and/or GzmB bound and/or entered uninfected Retics or iRetics (Fig. 4a–f). GNLY, but not GzmB on its own, selectively
bound to iRetics, but not uninfected Retics (Fig.
4a–d). Moreover, when GNLY was present, virtually all iRetics, but
not uninfected Retics, stained with GzmB (Fig.
4e,f). GNLY co-localized with CD235a on the iRetic membrane, while GzmB was
internalized and co-localized with intracellular P. vivax, stained with
a Hoechst DNA dye (Fig. 4g, Supplementary Fig. 4). In some iRetic, GzmB
also showed punctate host cell staining, which might represent GzmB trafficking to host
mitochondria, where Gzms concentrate[31]. Thus, GNLY, independently of PFN, delivers GzmB to the parasite, a
surprising finding, since in other intracellular parasite infections, PFN is required to
deliver GNLY and Gzms across host cell membranes[5].
Figure 4
Granulysin binds to infected reticulocytes and mediates host cell lysis and
parasite killing
a–f, Imaging flow cytometry analysis of uptake of GzmB-AF488
(a,b) or GNLY-AF488 (c,d) on their own, or of
GzmB-AF488 in the presence of unlabeled GNLY (e,f) by healthy donor
(HD) unifected Retics (uRetics) and by uRetics and infected retics (iRetics)
from acute untreated P. vivax patients (Pv).
(a,c,e) show representative images, while (b,d,f)
show mean ± SEM of 3 HD and Pv samples. g, Imaging flow
cytometry images of Pv uRetic and iRetics incubated with GzmB-AF488 and
GNLY-AF750, and stained for CD235a and with a Hoechst dye to stain parasite DNA.
BF, bright field. This experiment was repeated three times with similar results.
h–j, Effect of mβCD depletion of cholesterol in
HD RBCs on binding of GNLY-AF488 on its own (n=4). Shown p values are in
comparison to intact RBC. (h) and of GzmB-AF488 in the presence of
unlabeled GNLY (n=3) (i); and on RBC lysis by increasing
amounts of GNLY, assessed by LHD release (n=4). k,l,
Staining of HD uRetics and of untreated Pv patient uRetics and iRetics with the
cholesterol analog 25-NBD (n=3). Representative images are shown in
(k) (n=5) and the proportion of cells with detectable
25-NBD fluorescence is shown in (l) (n=4).
m,n, Cytolysis of Pv iRetics (m, n=5) or
HD uRetics (n, n=4) after 1 hr incubation with GzmB
± GNLY ± PFN, assessed by LDH release. o, Effect of
incubation of iRetics from 4 Pv patients for 1 hr with indicated cytotoxic
granule proteins on parasite invasion of fresh Retics, assessed by Giemsa
staining. p–r, Electron micrographs of iRetics that were
untreated or incubated with GNLY ± GzmB. Higher magnification images
after treatment with GNLY plus GzmB in (q) show parasitophorous
vacuole membrane disruption ( ) and
chromatin condensation ( ) (left);
cytoplasmic vacuolization ( ) and
dense granules ( ) (middle); and
mitochondrial swelling ( ) (right).
Higher magnification images of untreated cells (r) show intact
digestive vacuole ( ),
parasitophorous vacuole membrane ( ) and mitochondria ( ). These
experiments were repeated three times with similar results (p,r). Graphs show
mean ± SEM; statistics in (b,d,f,j,l–o) were
analyzed by one-way ANOVA and in (h,i) by two-tailed non-parametric
paired t-test at 95% CI.
GNLY permeabilizes cholesterol-containing mammalian cell membranes only at
exceedingly high (micromolar) concentrations, since cholesterol inhibits pore
formation[8]. In contrast, PFN is
a cholesterol-dependent cytolysin. Other Plasmodium species harvest and
deplete cholesterol from RBC membranes[32,33], which could make
them susceptible to GNLY. When we depleted cholesterol from RBC membranes using
methyl-β-cyclodextrin (mβCD), AF488-labeled GNLY attached to the
cholesterol-depleted, but not to untreated, RBC membranes (Fig. 4h), delivered GzmB-AF488 into the RBC (Fig. 4i), and lysed cholesterol-depleted RBCs (Fig. 4j). To determine whether cholesterol was depleted from iRetic
membranes, we stained Retics with
25-[N-[(7-nitro-2-1,3-benzoxadiazol-4-yl)methyl]amino]-27-norcholesterol
(25-NBD-cholesterol), a fluorescent cholesterol mimic. iRetics, but not uninfected
Retics, stained brightly with 25-NBD-cholesterol (Fig.
4k,l), suggesting that P. vivax also harvests cholesterol
from iRetic membranes, making them GNLY-susceptible.GNLY-delivered GzmB co-localization with the parasite (Fig. 4g) suggested that GNLY and GzmB would not only lyse
iRetics, but might also directly kill the parasite. To determine which cytotoxic
molecules are required to lyse iRetics and whether intracellular parasites are also
killed, we incubated GNLY, GzmB and/or PFN with iRetics (Fig. 4m) or HD uninfected Retics (Fig.
4n) for 1 hr and measured RBC lysis by LDH release and parasite viability by
the ability to invade fresh Retics[34]
(Fig. 4o). GNLY on its own lysed iRetics, but
GzmB or PFN, alone or together, had no significant effect. However, GNLY and GzmB was
significantly more cytotoxic than GNLY, and GzmB, GNLY and PFN further significantly
enhanced iRetic lysis. Importantly, uninfected Retics were unaffected by GzmB or GNLY,
but were lysed by PFN, as expected, because their membranes are cholesterol-rich. GNLY
alone inhibited parasite invasion of fresh RBC, but GNLY and GzmB together or all three
cytotoxic molecules completely blocked reinvasion. Reinvasion could be inhibited because
of parasite killing or because parasite maturation or infectious merozoite release was
hindered. To determine whether the parasites within iRetics were directly damaged, we
analyzed iRetic morphology by electron microscopy after treatment with GNLY±GzmB
(Fig. 4o). After just GNLY, the treated iRetics
swelled and the intracellular parasites started to show signs of death, such as
cytoplasmic vacuolization, consistent with iRetic membrane damage by GNLY. However,
after incubation with both GNLY and GzmB, intracellular parasites developed swollen and
fragmented mitochondria, condensed nuclei, and cytoplasmic vacuolization, and the
parasitophorous vacuole membrane was disrupted (Fig.
4p). These changes resembled morphological changes seen after GzmB and GNLY
treatment of other protozoan parasites[5]. The protocol used to select iRetics enriches for trophozoite stage
infection. Thus, GNLY and GzmB not only lyse iRetic, but also directly kill
intracellular trophozoites and block reinvasion.In conclusion, P. vivax iRetics highly express HLA-I and are
specifically recognized by CD8+ T cells. This is, to our knowledge, a
unique example of CD8+ T cells recognizing Retics in an
HLA-restricted antigen-specific manner. Because GNLY on its own delivers GzmB into
iRetics, the CTL mechanism that lyses iRetics is distinct from granule-mediated killing
of other mammalian target cells and intracellular parasites, which requires PFN. iRetic
lysis would be expected to reduce parasite infectivity by releasing parasites that have
not yet matured to the infectious merozoite stage from their obligate intracellular
niche. However, here we provide evidence that CD8+ T cells also
directly kill P. vivax, which should enhance immune effectiveness by
limiting spreading of infectious organisms. Although patient CTLs lysed iRetics in a 12
hr assay, parasite killing and inhibition of reinvasion occurred within an hour of
adding GNLY and GzmB, suggesting that parasite death is rapid. The molecular mechanism
of P. vivax killing remains to be defined, which will be challenging
without long-term culture systems for P. vivax. Nevertheless, our
findings identify a previously unsuspected protective mechanism against blood stage
parasites and suggest that a vaccine that elicits CTLs against blood stage P.
vivax may help prevent transmission and control disease severity. In the
future, it will be worthwhile to examine whether other innate or innate-like killer
lymphocytes that express GNLY, such as NK and γδ T cells, recognize and
kill iRetic and play a role in immune protection[35-39]. Future
studies are also needed to determine whether killer lymphocytes are always beneficial
during blood stage malaria, since they might contribute to anemia, inflammation or other
pathological sequelae of infection.
Methods
Malaria patients and healthy donors
Male and female healthy donors (HD) and P.
vivax-infected patients, aged 18–60, were recruited from the
Amazon malaria endemic area from the outpatientmalaria clinic in the Tropical
Medicine Research Center in Porto Velho, Brazil, with informed consent using a
protocol approved by the Institutional Review Boards of the Oswaldo Cruz
Foundation and National Ethical Council (CAAE: 59902816.7.0000.5091), University
of Massachusetts Medical School (11116) and Boston Children’s Hospital
(00005698). The exclusion criteria were co-infection with P.
falciparum, chronic inflammatory or infectious diseases or
pregnancy. Infected patients were clinically evaluated and tested for
Plasmodiuminfection by thick smear and PCR during
symptomatic stage and 40 days after treatment with chloroquine and primaquine.
All relevant ethical regulations were followed while conducting this work.
Reagents
All antibodies and fluorescent dies used in our experiments are listed
on Table S2.
Sample preparation
PBMCs, obtained by Ficoll (GE Healthcare, USA) gradient centrifugation
as previous described[40], were
stained for CD69, Ki67, HLA-DR, PFN, GNLY and GzmB. CD8+ and
CD4+ T cells were purified from PBMCs by positive
selection using Dynabeads (ThermoFisher Scientific). The RBC pellet, suspended
in isotonic Percoll, was used to purify iRetics from malariapatient samples on
a 45% isotonic Percoll (GE Healthcare, USA) gradient and uRetics from HD
on 70% Percoll. Uninfected erythrocytes (uRBCs) were obtained from the
Percoll gradient pellet.
T lymphocyte and RBC coculture
Purified T cells (105/well) and Retics (5 ×
105/well) were co-cultured at 37°C for 10 hr in 96-well
plates to assess T cell activation, IFNγ production and degranulation
(CD107a)[41]. Some
experiments were performed in the presence of 2 μg/ml HLA-ABC blocking
antibody (W6/33) or isotype control, which were added to CD8+
T cells 30 min before RBC coculture. T lymphocytes cultured with 1 μg/ml
anti-CD3 (BD Pharmingen) and 0.5 μg/ml anti-CD28 (BD Pharmingen) were
used as positive controls.
Flow cytometry
T cell surface were stained with anti-CD4, anti-CD8, anti-CD3,
anti-CD69, anti-HLA-DR, anti-Ki67, anti-CD19, anti-γδ TCR,
anti-αβ TCR, anti-CD56, anti-CD161 and anti-TCRVα7.2.
RBCs were stained with anti-CD71, anti-CD235a, anti-HLA-ABC (class I),
anti-HLA-DR (class II), Thiazole Orange and SYBR Green I (P.
vivax DNA)[25,42-44]. To analyze intracellular cytokine and
granule protein expression, cells were incubated at 37°C, 5%
CO2 in the presence of indicated stimuli for 30 min before adding
Brefeldin A (1μl/ml) and Monensin (1μl/ml) (BD Pharmingen)
solutions and culture for an additional 4–10 hr prior to staining. Cells
were first stained for indicated cell surface markers, then permeabilized in
Fix/Perm buffer, and stained in Perm/Wash buffer (BD Pharmingen) for
IFNγ or cytotoxic granule proteins as per the manufacturer’s
instructions. Flow cytometry was performed using a FACScan flow cytometer
(Becton Dickinson, USA), Fortessa (Becton Dickinson, USA) or Celesta (Becton
Dickinson, USA) and analyzed using FlowJo software V.10 (Tri-Star, USA).
Plasma granulysin
GNLY in plasma from healthy donors and P.
vivax-infected patients was measured using the HumanGranulysin DuoSet
ELISA (R&D Systems, USA).
Reticulocyte protein expression
Cell lysates of iRetics and HD uRetics, obtained by lysis in RIPA buffer
(Sigma-Aldrich) in the presence of complete protease inhibitor (Roche, CH), were
analyzed by immunoblot probed for TAP1 after hemoglobin removal using
HemogloBind (Biotech Support Group, USA). Each retic lane was loaded with 50
μg protein, while PBMC control sample contained 20 μg protein.
The same membrane was probed for β-actin and F-actin as loading
controls. β-actin was used as loading control for HD uRetics and F-actin
for iRetics because host cell remodeling of the actin cytoskeleton under
Plasmodiuminfection[45,46]. The
secondary anti-mouse or anti-rabbit IgG antibody was detected by
chemiluminescence.
Proteomic and transcriptomic analysis
Databases for the Retic proteome[23] and transcriptome[24] were analyzed for expression of proteins involved in
the endogenous antigen presentation pathway (Table S1) using ID_REF data
deposited in the Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/) (accession numbers:
GSM143572–143599, GSM143671–143682, GSM143703,
GSM143706–143716, GSM143718–143721).
Cytotoxic enzymes
GzmB, GNLY and PFN were purified from YT-Indy cells as
described[46]. Purity
was >95%, as determined by Coomassie stained SDS-PAGE. Protein
concentrations were determined by Bradford assay. Specific activity of GNLY and
PFN was determined by serial dilution on infected and uninfected reticulocytes;
a sublytic concentration (<20% killing, adequate to deliver Gzms, but
not kill most host cells) was used in all experiments. Specific activity of GzmB
was determined by cleavage of the peptide substrate,
t-Butyloxycarbonyl-Ala-Ala-Asp-ThioBenzyl ester (Boc-AAD-SBzl), in the presence
of 5,5′Dithio-bis (2-nitrobenzoic acid) (DTNB).
Reticulocyte lysis assay
iRetics labeled with carboxyfluorescein diacetate succinimidyl ester
(CFSE, Sigma-Aldrich) were cultured with CD8+ T cells at
indicated ratios. Twelve hours later, cells were harvested and stained for
CD235a and CD8. The number of surviving CFSE+ gated
CD235a+ cells was compared with the number of
CFSE+ cells surviving after culture in the absence of
lymphocytes. Lactate dehydrogenase (LDH) release, measured by CytoTox 96
(Promega, USA), was used to assess RBC lysis after co-culture for 12 hr with
CD8+ T cells at indicated E:T ratios. To assess cytolysis
by purified granule proteins, iRetics were incubated for 1 hr at 37°C
with 100 nM GNLY ± 500 nM GzmB ± a sublytic concentration of PFN
and the culture supernatants were analyzed by LDH release assay. The morphology
of treated Retics was assessed by electron microscopy.
Parasite invasion assay
Invasion assays were performed as previously described[47]. Infected reticulocytes from
P. vivaxmalariapatients, enriched on a 45%
Percoll gradient, were treated with 100 nM GNLY ± 500 nM GzmB ±
a sublytic concentration of PFN for 1 hr at 37°C. Uninfected HD
reticulocytes, obtained from a 70% Percoll gradient, were added to the
washed, treated iRetics at a ratio of 10:1. After 24 hr coculture, cytospins
were stained with Giemsa and the proportion of newly invaded ring stage-infected
cells was enumerated.
Imaging flow cytometry
Purified CD8+ T cells and Retics were co-cultured at
an E:T ratio of 1:5 for 1 hr and then stained with HLA-ABC, TCR, CD3, CD8 and
CD235a antibodies before analysis on an ImageStream Amnis X using Ideas software
(Amnis, USA). CD235a+CD3+ doublets were
selected based on aspect ratio versus cell area. Purified iRetics and uRetics
were incubated with 100 nM GNLY-Alexa Fluor 488 or 500 nM GzmB-Alexa Fluor 488
in the presence or absence of 100 nM unlabeled GNLY for 1 hr at 37°C as
described[1]. Cells were
washed and fixed with 2% PFA in PBS prior to imaging flow cytometry. The
frequency of cells staining for GNLY and GzmB was quantified using Ideas
software. To analyze colocalization, images of iRetics incubated for 1 hr with
100 nM GNLY-Alexa Fluor 647 and 500 nM GzmB-Alexa Fluor 488 were stained with
CD235a-PE and Hoechst 33342.
Cholesterol depletion
HD RBCs in HBSS were untreated or incubated with indicated
concentrations of methyl-beta-cyclodextrin for 30 min at 37°C before
adding indicated amounts of purified GNLY and GzmB or GzmB-Alexa Fluor 488 and
culturing for 1 h. Treated cells were analyzed by flow cytometry for GNLY and
GzmB uptake by flow cytometry or for LDH release as above.
Electron Microscopy
Purified iRetics incubated with 100 nM GNLY ± 500 nM GzmB were
fixed in 2.5% buffered glutaraldehyde solution, 0.1 M, pH 7.2, for 3 hr
at 4°C, washed and the cell pellet was immersed in 4% agarose.
The pellet was fixed in 1% osmium tetroxide and 1.5% (w/v)
potassium ferrocyanide, dehydrated in ethanol and embedded in Araldite 502
(Electron Microscopy Sciences, Hatfield, PA, USA). Extra thin sections, obtained
using a Sorvall MT-2B ultramicrotome (Dupont, USA), were applied to 200-mesh
copper grids (Ted Pella, USA) and stained with 2% uranyl acetate and
Reynolds’ lead citrate. Images were obtained by transmission electron
microscopy using a Tecnai G2-12 - SpiritBiotwin FEI -120 kV (FEI, JP).
Statistical Analysis
Statistical analysis was performed using GraphPad Prism V7.0. Prior to
applying statistical methods, whether the data fit a normal distribution was
evaluated by the D’Agostino and Pearson normality test. The distribution
was considered normal when p ≤ 0.05. Parametric or
non-parametric (Mann-Whitney test) two-tailed paired and unpaired
t-tests were used to compare two groups at 95%
confidence interval (CI). Multiple groups were compared by two-way ANOVA with
additional Tukey’s multiple comparisons test at 95% CI. Simple
column comparisons were analyzed by one-way ANOVA using the Kruskal-Wallis test
and Tukey’s multiple comparisons test at 95% CI. Differences
were considered statistically significant when p ≤
0.05. All the p values less them 0.0001 are shown as
p < 0.0001.
Authors: Marek Cyrklaff; Cecilia P Sanchez; Nicole Kilian; Cyrille Bisseye; Jacques Simpore; Friedrich Frischknecht; Michael Lanzer Journal: Science Date: 2011-11-10 Impact factor: 47.728
Authors: Farokh Dotiwala; Sachin Mulik; Rafael B Polidoro; James A Ansara; Barbara A Burleigh; Michael Walch; Ricardo T Gazzinelli; Judy Lieberman Journal: Nat Med Date: 2016-01-11 Impact factor: 53.440
Authors: Marieangela C Wilson; Kongtana Trakarnsanga; Kate J Heesom; Nicola Cogan; Carole Green; Ashley M Toye; Steve F Parsons; David J Anstee; Jan Frayne Journal: Mol Cell Proteomics Date: 2016-03-22 Impact factor: 5.911
Authors: Sung-Ho Goh; Matthew Josleyn; Y Terry Lee; Robert L Danner; Robert B Gherman; Maggie C Cam; Jeffery L Miller Journal: Physiol Genomics Date: 2007-04-03 Impact factor: 3.107
Authors: Bijay K Jha; Sanjay Varikuti; Abhay R Satoskar; Bradford S McGwire; Gabriella R Seidler; Greta Volpedo Journal: Infect Immun Date: 2020-06-22 Impact factor: 3.441
Authors: Melisa Gualdrón-López; Míriam Díaz-Varela; Haruka Toda; Iris Aparici-Herraiz; Laura Pedró-Cos; Ricardo Lauzurica; Marcus V G Lacerda; Marco Antonio Fernández-Sanmartín; Carmen Fernandez-Becerra; Hernando A Del Portillo Journal: Front Cell Infect Microbiol Date: 2021-03-01 Impact factor: 5.293
Authors: Jessica R Loughland; Tonia Woodberry; Matt Field; Dean W Andrew; Arya SheelaNair; Nicholas L Dooley; Kim A Piera; Fiona H Amante; Enny Kenangalem; Ric N Price; Christian R Engwerda; Nicholas M Anstey; James S McCarthy; Michelle J Boyle; Gabriela Minigo Journal: Clin Transl Immunology Date: 2020-06-18
Authors: Vinayaka Kotraiah; Timothy W Phares; Frances E Terry; Pooja Hindocha; Sarah E Silk; Carolyn M Nielsen; Leonard Moise; Kenneth D Tucker; Rebecca Ashfield; William D Martin; Anne S De Groot; Simon J Draper; Gabriel M Gutierrez; Amy R Noe Journal: Front Immunol Date: 2021-07-07 Impact factor: 7.561